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Abstract
Objective: A systematic review and a meta-analysis were carried out in order to summarize the current published studies
and to evaluate LINE-1 hypomethylation in blood and other tissues as an epigenetic marker for cancer risk.
Methods: A systematic literature search in the Medline database, using PubMed, was conducted for epidemiological
studies, published before March 2014. The random-effects model was used to estimate weighted mean differences (MDs)
with 95% Confidence Intervals (CIs). Furthermore, subgroup analyses were conducted by sample type (tissue or blood
samples), cancer types, and by assays used to measure global DNA methylation levels. The Cochrane software package
Review Manager 5.2 was used.
Results: A total of 19 unique articles on 6107 samples (2554 from cancer patients and 3553 control samples) were included
in the meta-analysis. LINE-1 methylation levels were significantly lower in cancer patients than in controls (MD: 26.40, 95%
CI:27.71,25.09; p,0.001). The significant difference in methylation levels was confirmed in tissue samples (MD27.55; 95%
CI: 29.14, 265.95; p,0.001), but not in blood samples (MD: 20.26, 95% CI: 20.69, 0.17; p = 0.23). LINE-1 methylation levels
were significantly lower in colorectal and gastric cancer patients than in controls (MD: 28.33; 95% CI: 210.56, 26.10; p,
0.001 and MD: 25.75; 95% CI: 27.75, 23.74; p,0.001) whereas, no significant difference was observed for hepatocellular
cancer.
Conclusions: The present meta-analysis adds new evidence to the growing literature on the role of LINE-1 hypomethylation
in human cancer and demonstrates that LINE-1 methylation levels were significantly lower in cancer patients than in control
samples, especially in certain cancer types. This result was confirmed in tissue samples, both fresh/frozen or FFPE specimens,
but not in blood. Further studies are needed to better clarify the role of LINE-1 methylation in specific subgroups,
considering both cancer and sample type, and the methods of measurement.
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Introduction
Epigenetic alterations, heritable DNA modifications that do not
involve changes in the DNA sequence, are associated with changes
in gene expression and are important in maintaining genomic
stability [1]. Among epigenetic mechanisms, DNA methylation is
the most commonly studied and involved in various biological
processes including cancer [2–5]. Global hypomethylation, an
overall genome-wide reduction in DNA methylation content, is
associated with genomic instability and an increased number of
mutational events [6]. Genomic DNA hypomethylation is likely to
result from demethylation in repetitive elements, which account
for about 55% of the human genome and determine gene
regulation and genomic stability [7,8]. Long Interspersed Nucle-
otide Element 1 (LINE-1) and Alu repetitive elements are major
constituents of interspersed DNA repeats. Due to their high
occurrence throughout the genome, methylation in repetitive
elements have been shown to correlate with global genomic DNA
methylation content and demethylation has been associated with
genome instability and chromosomal aberrations. Thus, LINE-1
and Alu have been used as global surrogate markers for estimating
the genomic DNA methylation level in cancer tissues [6,9–10] and
in peripheral blood leukocytes [11]. LINE-1 hypomethylation was
observed in several types of cancer [12–14] and was associated
with a poor prognosis [15]. In a meta-analysis [11], global DNA
hypomethylation in peripheral blood leukocytes was associated
with increased cancer risk. Another meta-analysis, investigating
genome-wide DNA methylation in peripheral blood DNA and
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cancer risk, reports a significant inverse association between
genomic 5-methylcytosine levels and cancer risk, but no overall
risk association using surrogates for genomic methylation,
including methylation at the LINE-1 and Alu repetitive elements
was found [16]. The aim of the present study was to carry out a
more comprehensive systematic review and a meta-analysis in
order to summarize the current published studies and to evaluate
LINE-1 hypomethylation in blood and other tissues as an
epigenetic marker for cancer risk.
Methods
Search strategy and selection criteria
A systematic literature search in the Medline database, using
PubMed, was carried out for epidemiological studies, published
before March 2014, investigating the association between LINE-1
hypomethylation and cancer risk. The searches were limited to
studies written in English; abstracts and unpublished studies were
not included. Literature search was conducted independently by
two Authors. The following selection criteria were used to search
articles and abstracts: (‘‘cancer’’ or ‘‘tumor’’ or ‘‘carcinoma’’)
AND (‘‘LINE-1’’ or ‘‘Long Interspersed Element-1’’ or ‘‘global’’)
AND (‘‘hypomethylation’’ or ‘‘methylation’’). Moreover, the
reference lists from selected articles were checked to search for
further relevant studies. No studies were excluded a priori for
weakness of design or data quality. Articles were included in the
quantitative analysis only if they satisfied the following criteria: (1)
case-control or cohort study designs; and (2) studies that reported
mean values and standard deviations (SD) of DNA methylation
level in cancer patients and in control group. Furthermore
exclusion criteria were as follows: (1) the study reporting only
results as median of the methylation levels or through graphic
display, or 95% confidence intervals (CIs) with adjusted odds ratios
(OR) or relative risks for cancer risk in subjects with the lowest
level of global DNA methylation (tertile, quartile or decile)
compared to group with the highest level, (2) the study reporting
only gene-specific DNA methylation analysis, and (3) review
articles.
Where there were missing data or additional information were
required, study Authors were contacted by email.
The preferred reporting items for systematic reviews and meta-
analysis (PRISMA) guidelines for the conduct of meta-analysis
were followed [17].
Data collection and extraction
Two of the Authors independently reviewed all the eligible
studies and abstracted the following information in a standard
format: first Author’s last name, year of publication, country where
the study was performed, study design, cancer sites and types,
sample type, experimental methods to measure global DNA
methylation levels, number of cases and controls, mean values and
SD of global DNA methylation levels for each group and main
results.
Figure 1. Flow diagram of study selection.
doi:10.1371/journal.pone.0109478.g001
Hypomethylation and Cancer: A Meta-Analysis
PLOS ONE | www.plosone.org 2 October 2014 | Volume 9 | Issue 10 | e109478
T
a
b
le
1
.
St
u
d
ie
s
in
cl
u
d
e
d
in
th
e
sy
st
e
m
at
ic
re
vi
e
w
an
d
in
th
e
m
e
ta
-a
n
al
ys
is
.
A
u
th
o
r
(Y
e
a
r)
C
o
u
n
tr
y
S
tu
d
y
d
e
si
g
n
C
a
n
ce
r
ty
p
e
S
a
m
p
le
ty
p
e
A
ss
a
y
N
u
m
b
e
r
o
f
ca
se
s/
co
n
tr
o
ls
M
e
a
n
(S
D
)
C
a
se
s
M
e
a
n
(S
D
)
C
o
n
tr
o
ls
R
e
su
lt
s
A
n
te
lo
(2
0
1
2
)a
*
A
rg
e
n
ti
n
a
R
e
tr
o
sp
e
ct
iv
e
C
o
lo
re
ct
al
(E
ar
ly
O
n
se
t)
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
1
8
5
/3
2
5
6
.6
(8
.6
)
7
5
.5
(1
.5
)
Ea
rl
y-
o
n
se
t
C
R
C
h
ad
si
g
n
if
ic
an
tl
y
lo
w
e
r
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
th
an
an
y
o
th
e
r
g
ro
u
p
A
n
te
lo
(2
0
1
2
)b
*
A
rg
e
n
ti
n
a
R
e
tr
o
sp
e
ct
iv
e
C
o
lo
re
ct
al
(L
yn
ch
Sy
n
d
ro
m
e
)
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
2
0
/3
2
6
6
.3
(4
.5
)
7
5
.5
(1
.5
)
A
n
te
lo
(2
0
1
2
)c
*
A
rg
e
n
ti
n
a
R
e
tr
o
sp
e
ct
iv
e
C
o
lo
re
ct
al
(O
ld
e
r
O
n
se
t
sp
o
ra
d
ic
M
SI
-h
ig
h
)
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
4
6
/3
2
6
7
.1
(5
.5
)
7
5
.5
(1
.5
)
A
n
te
lo
(2
0
1
2
)d
*
A
rg
e
n
ti
n
a
R
e
tr
o
sp
e
ct
iv
e
C
o
lo
re
ct
al
(O
ld
e
r
O
n
se
t
sp
o
ra
d
ic
M
SS
/M
SI
-l
o
w
)
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
8
9
/3
2
6
5
.1
(6
.3
)
7
5
.5
(1
.5
)
C
h
o
i
(2
0
0
7
)*
U
SA
R
e
tr
o
sp
e
ct
iv
e
N
e
u
ro
e
n
d
o
cr
in
e
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
3
5
/3
5
6
8
.5
(1
0
.0
)
8
0
.0
(7
.1
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
D
as
ka
lo
s
(2
0
0
9
)*
U
K
R
e
tr
o
sp
e
ct
iv
e
Lu
n
g
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
4
8
/4
8
5
4
.3
6
(1
0
.5
2
)
6
9
.5
6
(1
.1
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
Es
te
ci
o
(2
0
0
7
)*
U
SA
R
e
tr
o
sp
e
ct
iv
e
C
o
lo
re
ct
al
an
d
va
ri
o
u
s
ca
n
ce
r
ce
ll
lin
e
s
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
6
0
/6
0
5
4
.9
(1
.1
)
6
4
.3
(0
.5
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
H
u
r
(2
0
1
4
)*
Sp
ai
n
R
e
tr
o
sp
e
ct
iv
e
C
o
lo
re
ct
al
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
7
7
/7
7
6
6
.2
(5
.3
)
7
5
.8
(3
.1
0
)
C
o
m
p
ar
e
d
w
it
h
n
o
rm
al
ad
ja
ce
n
t
m
u
co
sa
,
b
o
th
p
ri
m
ar
y
ca
n
ce
r
an
d
m
e
ta
st
as
is
ti
ss
u
e
w
e
re
si
g
n
if
ic
an
tl
y
h
yp
o
m
e
th
yl
at
e
d
at
LI
N
E-
1
e
le
m
e
n
ts
Iw
ag
am
i
(2
0
1
3
)*
Ja
p
an
P
ro
sp
e
ct
iv
e
Es
o
p
h
ag
e
al
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
5
0
/5
0
6
3
.3
(1
2
.7
)
7
8
.8
(6
.2
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
Le
e
(2
0
0
8
)*
Sw
e
d
e
n
R
e
tr
o
sp
e
ct
iv
e
T
h
yr
o
id
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
2
1
/2
1
7
1
.3
(2
.6
)
7
1
.8
(3
.4
)
LI
N
E-
1
m
e
th
yl
at
io
n
ch
an
g
e
s
ar
e
n
o
t
o
b
se
rv
e
d
b
e
tw
e
e
n
ca
n
ce
r
an
d
n
o
rm
al
ti
ss
u
e
s
Le
e
(2
0
1
1
)*
So
u
th
K
o
re
a
R
e
tr
o
sp
e
ct
iv
e
G
as
tr
ic
T
is
su
e
C
O
B
R
A
LI
N
E-
1
5
3
/5
3
4
0
.2
3
(0
.9
2
)
4
5
.9
4
(1
.7
8
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
M
at
su
n
o
ki
(2
0
1
2
)*
Ja
p
an
R
e
tr
o
sp
e
ct
iv
e
C
o
lo
re
ct
al
T
is
su
e
M
u
lt
ic
o
lo
rM
e
th
yL
ig
h
t
A
ss
ay
4
8
/4
8
6
3
.6
1
(1
3
.9
1
)
6
2
.5
4
(1
4
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
Hypomethylation and Cancer: A Meta-Analysis
PLOS ONE | www.plosone.org 3 October 2014 | Volume 9 | Issue 10 | e109478
T
a
b
le
1
.
C
o
n
t.
A
u
th
o
r
(Y
e
a
r)
C
o
u
n
tr
y
S
tu
d
y
d
e
si
g
n
C
a
n
ce
r
ty
p
e
S
a
m
p
le
ty
p
e
A
ss
a
y
N
u
m
b
e
r
o
f
ca
se
s/
co
n
tr
o
ls
M
e
a
n
(S
D
)
C
a
se
s
M
e
a
n
(S
D
)
C
o
n
tr
o
ls
R
e
su
lt
s
P
av
ic
ic
(2
0
1
2
)a
*
Fi
n
la
n
d
R
e
tr
o
sp
e
ct
iv
e
C
o
lo
re
ct
al
(S
p
o
ra
d
ic
M
SS
)
T
is
su
e
M
S-
M
LP
A
5
5
/5
5
8
5
(6
)
9
3
(2
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
P
av
ic
ic
(2
0
1
2
)b
*
Fi
n
la
n
d
R
e
tr
o
sp
e
ct
iv
e
C
o
lo
re
ct
al
(S
p
o
ra
d
ic
M
SI
)
T
is
su
e
M
S-
M
LP
A
5
2
/5
2
8
7
(5
)
9
1
(4
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
P
av
ic
ic
(2
0
1
2
)c
*
Fi
n
la
n
d
R
e
tr
o
sp
e
ct
iv
e
C
o
lo
re
ct
al
(L
yn
ch
Sy
n
d
ro
m
e
)
T
is
su
e
M
S-
M
LP
A
4
3
/4
3
8
4
(6
)
9
0
(5
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
P
av
ic
ic
(2
0
1
2
)d
*
Fi
n
la
n
d
R
e
tr
o
sp
e
ct
iv
e
C
o
lo
re
ct
al
(F
C
C
X
)
T
is
su
e
M
S-
M
LP
A
1
8
/1
8
8
0
(8
)
8
4
(6
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
P
av
ic
ic
(2
0
1
2
)e
*
Fi
n
la
n
d
R
e
tr
o
sp
e
ct
iv
e
G
as
tr
ic
(S
p
o
ra
d
ic
M
SS
)
T
is
su
e
M
S-
M
LP
A
3
4
/3
4
7
9
(1
2
)
9
0
(5
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
P
av
ic
ic
(2
0
1
2
)f
*
Fi
n
la
n
d
R
e
tr
o
sp
e
ct
iv
e
G
as
tr
ic
(S
p
o
ra
d
ic
M
SI
)
T
is
su
e
M
S-
M
LP
A
1
1
/1
1
8
8
(4
)
9
0
(4
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
P
av
ic
ic
(2
0
1
2
)g
*
Fi
n
la
n
d
R
e
tr
o
sp
e
ct
iv
e
G
as
tr
ic
(L
yn
ch
Sy
n
d
ro
m
e
)
T
is
su
e
M
S-
M
LP
A
1
3
/1
3
8
6
(5
)
9
0
(5
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
P
av
ic
ic
(2
0
1
2
)h
*
Fi
n
la
n
d
R
e
tr
o
sp
e
ct
iv
e
En
d
o
m
e
tr
ia
l
(L
yn
ch
Sy
n
d
ro
m
e
)
T
is
su
e
M
S-
M
LP
A
5
0
/5
0
8
8
(7
)
9
0
(7
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
Sh
ig
ak
i
(2
0
1
3
)*
Ja
p
an
P
ro
sp
e
ct
iv
e
G
as
tr
ic
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
7
4
/7
4
7
2
.3
(1
0
.1
)
7
9
.2
(5
.6
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
ti
ss
u
e
s
th
an
in
n
o
rm
al
ad
ja
ce
n
t
ti
ss
u
e
s
Sh
u
an
g
sh
o
ti
(2
0
0
7
)*
T
h
ai
la
n
d
R
e
tr
o
sp
e
ct
iv
e
C
e
rv
ix
u
te
ri
n
e
T
is
su
e
C
O
B
R
A
LI
N
E-
1
7
/1
5
3
5
.6
3
(7
.3
2
)
4
0
.6
(8
.8
6
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
p
at
ie
n
ts
th
an
in
h
e
al
th
y
su
b
je
ct
s
Su
b
b
al
e
kh
a
(2
0
0
8
)*
T
h
ai
la
n
d
R
e
tr
o
sp
e
ct
iv
e
H
e
ad
an
d
N
e
ck
O
ra
l
ri
n
se
s
C
O
B
R
A
LI
N
E-
1
3
8
/3
7
3
7
.5
3
(2
.6
1
)
4
1
.7
8
(2
.8
4
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
p
at
ie
n
ts
th
an
in
h
e
al
th
y
su
b
je
ct
s
Hypomethylation and Cancer: A Meta-Analysis
PLOS ONE | www.plosone.org 4 October 2014 | Volume 9 | Issue 10 | e109478
T
a
b
le
1
.
C
o
n
t.
A
u
th
o
r
(Y
e
a
r)
C
o
u
n
tr
y
S
tu
d
y
d
e
si
g
n
C
a
n
ce
r
ty
p
e
S
a
m
p
le
ty
p
e
A
ss
a
y
N
u
m
b
e
r
o
f
ca
se
s/
co
n
tr
o
ls
M
e
a
n
(S
D
)
C
a
se
s
M
e
a
n
(S
D
)
C
o
n
tr
o
ls
R
e
su
lt
s
C
as
h
(2
0
1
2
)*
C
h
in
a
R
e
tr
o
sp
e
ct
iv
e
B
la
d
d
e
r
B
lo
o
d
P
yr
o
se
q
u
e
n
ci
n
g
5
1
0
/5
2
8
8
1
.8
6
(1
.8
2
)
8
1
.9
6
(1
.8
9
)
LI
N
E-
1
m
e
th
yl
at
io
n
w
e
re
co
m
p
ar
ab
le
in
ca
se
s
an
d
co
n
tr
o
ls
Li
ao
(2
0
1
1
)*
C
e
n
tr
al
an
d
e
as
te
rn
Eu
ro
p
e
R
e
tr
o
sp
e
ct
iv
e
R
e
n
al
ce
ll
B
lo
o
d
P
yr
o
se
q
u
e
n
ci
n
g
3
2
8
/6
5
4
8
2
.1
3
(1
.8
6
)
8
1
.7
4
(1
.9
8
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
h
ig
h
e
r
in
ca
n
ce
r
p
at
ie
n
ts
th
an
in
h
e
al
th
y
su
b
je
ct
s
M
ir
ab
e
llo
(2
0
1
0
)*
U
SA
R
e
tr
o
sp
e
ct
iv
e
T
e
st
ic
u
la
r
B
lo
o
d
P
yr
o
se
q
u
e
n
ci
n
g
1
5
2
/2
5
5
7
9
.1
(0
.1
7
7
)
7
9
.3
(0
.1
2
8
)
T
h
e
re
w
as
n
o
si
g
n
if
ic
an
t
d
if
fe
re
n
ce
b
e
tw
e
e
n
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
in
ca
se
s
an
d
co
n
tr
o
ls
R
am
zy
(2
0
1
1
)*
Eg
yp
t
R
e
tr
o
sp
e
ct
iv
e
H
e
p
at
o
ce
llu
la
r
B
lo
o
d
C
O
B
R
A
LI
N
E-
1
5
0
/1
0
4
1
.8
6
(1
0
.0
6
)
5
4
.0
0
(7
.8
2
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
p
at
ie
n
ts
th
an
in
h
e
al
th
y
su
b
je
ct
s
T
an
g
ki
jv
an
ic
h
(2
0
0
7
)*
T
h
ai
la
n
d
R
e
tr
o
sp
e
ct
iv
e
H
e
p
at
o
ce
llu
la
r
B
lo
o
d
C
O
B
R
A
LI
N
E-
1
8
5
/3
0
4
6
.8
3
(7
.7
4
)
5
3
.4
5
(4
.2
9
)
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
p
at
ie
n
ts
th
an
in
h
e
al
th
y
su
b
je
ct
s
W
u
(2
0
1
2
)*
T
ai
w
an
R
e
tr
o
sp
e
ct
iv
e
H
e
p
at
o
ce
llu
la
r
B
lo
o
d
P
yr
o
se
q
u
e
n
ci
n
g
3
0
2
/1
2
5
0
7
6
.2
(2
.2
)
7
6
.2
(2
.1
)
T
h
e
re
w
as
n
o
si
g
n
if
ic
an
t
d
if
fe
re
n
ce
b
e
tw
e
e
n
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
in
ca
se
s
an
d
co
n
tr
o
ls
B
ab
a
(2
0
1
0
)
U
SA
P
ro
sp
e
ct
iv
e
C
o
lo
re
ct
al
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
8
6
9
/N
A
T
u
m
o
r
LI
N
E-
1
m
e
th
yl
at
io
n
d
at
a
in
d
ic
at
e
e
n
o
rm
o
u
s
e
p
ig
e
n
o
m
ic
d
iv
e
rs
it
y
o
f
in
d
iv
id
u
al
co
lo
re
ct
al
ca
n
ce
rs
B
ae
(2
0
1
2
)
So
u
th
K
o
re
a
P
ro
sp
e
ct
iv
e
G
as
tr
ic
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
4
4
7
(t
w
o
se
ts
o
f
2
4
9
an
d
1
9
8
)/
N
A
LI
N
E-
1
h
yp
o
m
e
th
yl
at
io
n
is
an
e
ar
ly
e
ve
n
t
in
ca
rc
in
o
g
e
n
e
si
s
an
d
it
m
ay
b
e
a
p
ro
g
n
o
st
ic
in
d
ic
at
o
r
in
d
e
p
e
n
d
e
n
t
o
f
ca
n
ce
r
st
ag
e
B
o
lla
ti
(2
0
0
9
)
It
al
y
R
e
tr
o
sp
e
ct
iv
e
M
u
lt
ip
le
M
ye
lo
m
a
B
o
n
e
m
ar
ro
w
as
p
ir
at
e
s
P
yr
o
se
q
u
e
n
ci
n
g
7
6
/1
1
C
as
e
s
sh
o
w
e
d
a
d
e
cr
e
as
e
o
f
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
co
m
p
ar
e
d
to
co
n
tr
o
ls
C
h
al
it
ch
ag
o
rn
(2
0
0
4
)
T
h
ai
la
n
d
R
e
tr
o
sp
e
ct
iv
e
G
as
tr
ic
B
lo
o
d
C
O
B
R
A
LI
N
E-
1
1
7
/1
7
C
as
e
s
sh
o
w
e
d
a
d
e
cr
e
as
e
o
f
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
co
m
p
ar
e
d
to
co
n
tr
o
ls
C
h
o
i
(2
0
0
9
)
U
SA
R
e
tr
o
sp
e
ct
iv
e
B
re
as
t
B
lo
o
d
P
yr
o
se
q
u
e
n
ci
n
g
1
9
/1
8
T
h
e
re
w
as
n
o
si
g
n
if
ic
an
t
d
if
fe
re
n
ce
b
e
tw
e
e
n
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
in
ca
se
s
an
d
co
n
tr
o
ls
Hypomethylation and Cancer: A Meta-Analysis
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e109478
T
a
b
le
1
.
C
o
n
t.
A
u
th
o
r
(Y
e
a
r)
C
o
u
n
tr
y
S
tu
d
y
d
e
si
g
n
C
a
n
ce
r
ty
p
e
S
a
m
p
le
ty
p
e
A
ss
a
y
N
u
m
b
e
r
o
f
ca
se
s/
co
n
tr
o
ls
M
e
a
n
(S
D
)
C
a
se
s
M
e
a
n
(S
D
)
C
o
n
tr
o
ls
R
e
su
lt
s
D
am
m
an
n
(2
0
1
0
)
G
e
rm
an
y
R
e
tr
o
sp
e
ct
iv
e
O
va
ri
an
T
is
su
e
Q
U
B
R
A
2
2
/N
A
H
ig
h
p
re
va
le
n
ce
o
f
LI
N
E1
h
yp
o
m
e
th
yl
at
io
n
th
ro
u
g
h
o
u
t
al
l
tu
m
o
r
st
ag
e
s
D
i
(2
0
1
1
)
C
h
in
a
R
e
tr
o
sp
e
ct
iv
e
H
e
p
at
o
ce
llu
la
r
B
lo
o
d
P
yr
o
se
q
u
e
n
ci
n
g
3
1
5
/3
5
6
H
yp
o
m
e
th
yl
at
io
n
le
ad
to
a
si
g
n
if
ic
an
t
2
.6
-f
o
ld
in
cr
e
as
e
d
ri
sk
fo
r
H
C
C
Fa
b
ri
s
(2
0
1
1
)
It
al
y
R
e
tr
o
sp
e
ct
iv
e
C
h
ro
n
ic
ly
m
p
h
o
cy
ti
c
le
u
ke
m
ia
B
lo
o
d
P
yr
o
se
q
u
e
n
ci
n
g
7
7
/7
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
p
at
ie
n
ts
th
an
in
h
e
al
th
y
su
b
je
ct
s
G
ao
(2
0
1
2
)
C
h
in
a
R
e
tr
o
sp
e
ct
iv
e
G
as
tr
ic
B
lo
o
d
P
yr
o
se
q
u
e
n
ci
n
g
1
9
2
/3
8
4
T
h
e
re
w
as
n
o
si
g
n
if
ic
an
t
d
if
fe
re
n
ce
b
e
tw
e
e
n
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
in
ca
se
s
an
d
co
n
tr
o
ls
G
ao
(2
0
1
3
)
C
h
in
a
P
ro
sp
e
ct
iv
e
H
e
p
at
o
ce
llu
la
r
T
is
su
e
Se
q
u
e
n
ci
n
g
an
d
R
e
al
-t
im
e
q
P
C
R
2
4
3
/4
8
H
yp
o
m
e
th
yl
at
io
n
o
f
LI
N
E-
1
w
as
as
so
ci
at
e
d
w
it
h
tu
m
o
u
r
p
ro
g
re
ss
io
n
,
la
rg
e
r
tu
m
o
u
r
si
ze
,
h
ig
h
e
r
re
cu
rr
e
n
ce
ra
te
s,
w
o
rs
e
tu
m
o
u
r
st
ag
e
an
d
p
o
o
r
tu
m
o
u
r
d
if
fe
re
n
ti
at
io
n
G
e
li
(2
0
0
8
)
Sw
e
d
e
n
R
e
tr
o
sp
e
ct
iv
e
P
h
e
o
ch
ro
m
o
cy
to
m
a
an
d
P
ar
ag
an
g
lio
m
a
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
5
5
/N
A
C
as
e
s
sh
o
w
e
d
a
d
e
cr
e
as
e
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
co
m
p
ar
e
d
w
it
h
co
n
tr
o
ls
H
si
u
n
g
(2
0
0
7
)
U
SA
R
e
tr
o
sp
e
ct
iv
e
H
e
ad
an
d
N
e
ck
B
lo
o
d
C
O
B
R
A
LI
N
E-
1
2
7
8
/5
2
6
T
h
e
m
e
d
ia
n
m
e
th
yl
at
io
n
le
ve
l
in
co
n
tr
o
ls
w
as
sl
ig
h
tl
y
b
u
t
si
g
n
if
ic
an
tl
y
h
ig
h
e
r
th
an
th
e
m
e
d
ia
n
le
ve
l
in
ca
se
s.
H
yp
o
m
e
th
yl
at
io
n
le
ad
to
a
si
g
n
if
ic
an
t
1
.6
-f
o
ld
in
cr
e
as
e
d
ri
sk
fo
r
d
is
e
as
e
H
o
u
(2
0
1
0
)
P
o
la
n
d
R
e
tr
o
sp
e
ct
iv
e
G
as
tr
ic
B
lo
o
d
P
yr
o
se
q
u
e
n
ci
n
g
3
0
2
/4
2
1
C
an
ce
r
ri
sk
w
as
h
ig
h
e
st
am
o
n
g
th
o
se
w
it
h
lo
w
e
st
le
ve
l
o
f
m
e
th
yl
at
io
n
in
LI
N
E-
1
re
la
ti
ve
to
th
o
se
w
it
h
th
e
h
ig
h
e
st
le
ve
ls
,
al
th
o
u
g
h
th
e
tr
e
n
d
s
w
e
re
n
o
t
st
at
is
ti
ca
lly
si
g
n
if
ic
an
t
Ig
ar
as
h
i
(2
0
1
0
)
Ja
p
an
R
e
tr
o
sp
e
ct
iv
e
G
IS
T
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
1
0
6
/N
A
LI
N
E-
1
h
yp
o
m
e
th
yl
at
io
n
co
rr
e
la
te
s
si
g
n
if
ic
an
tl
y
w
it
h
th
e
ag
g
re
ss
iv
e
n
e
ss
o
f
tu
m
o
rs
an
d
it
co
u
ld
b
e
a
u
se
fu
l
m
ar
ke
r
fo
r
ri
sk
as
se
ss
m
e
n
t
Hypomethylation and Cancer: A Meta-Analysis
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e109478
T
a
b
le
1
.
C
o
n
t.
A
u
th
o
r
(Y
e
a
r)
C
o
u
n
tr
y
S
tu
d
y
d
e
si
g
n
C
a
n
ce
r
ty
p
e
S
a
m
p
le
ty
p
e
A
ss
a
y
N
u
m
b
e
r
o
f
ca
se
s/
co
n
tr
o
ls
M
e
a
n
(S
D
)
C
a
se
s
M
e
a
n
(S
D
)
C
o
n
tr
o
ls
R
e
su
lt
s
K
re
im
e
r
(2
0
1
3
)
G
e
rm
an
y
R
e
tr
o
sp
e
ct
iv
e
B
la
d
d
e
r
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
2
3
/1
2
LI
N
E-
1
m
e
th
yl
at
io
n
w
as
si
g
n
if
ic
an
tl
y
d
e
cr
e
as
e
d
in
ca
n
ce
rs
co
m
p
ar
e
d
to
n
o
rm
al
ti
ss
u
e
s
w
it
h
st
ri
ki
n
g
d
if
fe
re
n
ce
s
in
th
e
ir
p
e
rc
e
n
t
m
e
d
ia
n
va
lu
e
s
O
g
in
o
(2
0
0
8
)
U
SA
P
ro
sp
e
ct
iv
e
C
o
lo
re
ct
al
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
6
4
3
/N
A
LI
N
E-
1
h
yp
o
m
e
th
yl
at
io
n
w
as
lin
e
ar
ly
as
so
ci
at
e
d
w
it
h
a
st
at
is
ti
ca
lly
si
g
n
if
ic
an
t
in
cr
e
as
e
in
ca
n
ce
r
–
sp
e
ci
fi
c
m
o
rt
al
it
y
P
h
o
ka
e
w
(2
0
0
8
)
T
h
ai
la
n
d
R
e
tr
o
sp
e
ct
iv
e
H
e
ad
an
d
N
e
ck
T
is
su
e
C
O
B
R
A
LI
N
E-
1
1
1
/1
2
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
l
at
e
ac
h
lo
cu
s
is
d
if
fe
re
n
t,
it
ca
n
b
e
in
fl
u
e
n
ce
d
d
if
fe
re
n
ti
al
ly
d
e
p
e
n
d
in
g
o
n
w
h
e
re
th
e
p
ar
ti
cu
la
r
se
q
u
e
n
ce
s
ar
e
lo
ca
te
d
in
th
e
g
e
n
o
m
e
P
o
b
so
o
k
(2
0
1
1
)
T
h
ai
la
n
d
R
e
tr
o
sp
e
ct
iv
e
H
e
ad
an
d
N
e
ck
V
ar
io
u
s
C
O
B
R
A
LI
N
E-
1
9
0
/1
1
4
LI
N
E-
1
p
ar
ti
al
m
e
th
yl
at
io
n
re
p
re
se
n
ts
h
yp
o
m
e
th
yl
at
io
n
in
n
o
rm
al
ce
lls
b
u
t
h
yp
e
rm
e
th
yl
at
io
n
in
ca
n
ce
r
ce
lls
Sa
it
o
(2
0
1
0
)
Ja
p
an
R
e
tr
o
sp
e
ct
iv
e
Lu
n
g
T
is
su
e
R
e
al
-t
im
e
P
C
R
3
7
9
/3
3
3
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
w
e
re
si
g
n
if
ic
an
tl
y
lo
w
e
r
in
ca
n
ce
r
p
at
ie
n
ts
th
an
in
h
e
al
th
y
su
b
je
ct
s
Si
g
al
o
tt
i
(2
0
1
1
)
It
al
y
R
e
tr
o
sp
e
ct
iv
e
M
e
la
n
o
m
a
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
4
2
/4
LI
N
E-
1
m
e
th
yl
at
io
n
is
id
e
n
ti
fi
e
d
as
a
m
o
le
cu
la
r
m
ar
ke
r
o
f
p
ro
g
n
o
si
s
Su
n
am
i
(2
0
1
1
)
U
SA
R
e
tr
o
sp
e
ct
iv
e
C
o
lo
re
ct
al
T
is
su
e
A
Q
A
M
A
-P
C
R
1
1
7
/1
1
7
LI
N
E-
1
h
yp
o
m
e
th
yl
at
io
n
w
as
si
g
n
if
ic
an
tl
y
g
re
at
e
r
in
ad
e
n
o
m
a
ti
ss
u
e
co
m
p
ar
e
d
to
it
s
co
n
ti
g
u
o
u
s
n
o
rm
al
e
p
it
h
e
liu
m
an
d
ca
n
ce
r
m
e
se
n
ch
ym
al
ti
ss
u
e
T
ra
n
ke
n
sc
h
u
h
(2
0
1
0
)
G
e
rm
an
y
R
e
tr
o
sp
e
ct
iv
e
FL
C
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
2
5
/1
5
N
o
e
vi
d
e
n
ce
o
f
g
lo
b
al
h
yp
o
m
e
th
yl
at
io
n
w
as
fo
u
n
d
V
an
H
o
e
se
l
(2
0
1
2
)
U
SA
P
ro
sp
e
ct
iv
e
B
re
as
t
T
is
su
e
A
Q
A
M
A
-P
C
R
1
2
9
/1
0
9
LI
N
E-
1
h
yp
o
m
e
th
yl
at
io
n
is
a
p
ro
g
n
o
st
ic
b
io
m
ar
ke
r
o
f
p
o
o
r
o
u
tc
o
m
e
Hypomethylation and Cancer: A Meta-Analysis
PLOS ONE | www.plosone.org 7 October 2014 | Volume 9 | Issue 10 | e109478
T
a
b
le
1
.
C
o
n
t.
A
u
th
o
r
(Y
e
a
r)
C
o
u
n
tr
y
S
tu
d
y
d
e
si
g
n
C
a
n
ce
r
ty
p
e
S
a
m
p
le
ty
p
e
A
ss
a
y
N
u
m
b
e
r
o
f
ca
se
s/
co
n
tr
o
ls
M
e
a
n
(S
D
)
C
a
se
s
M
e
a
n
(S
D
)
C
o
n
tr
o
ls
R
e
su
lt
s
W
ilh
e
lm
2
0
1
0
U
SA
R
e
tr
o
sp
e
ct
iv
e
B
la
d
d
e
r
B
lo
o
d
P
yr
o
se
q
u
e
n
ci
n
g
2
8
5
/4
6
5
B
e
in
g
in
th
e
lo
w
e
st
LI
N
E1
m
e
th
yl
at
io
n
d
e
ci
le
w
as
as
so
ci
at
e
d
w
it
h
a
si
g
n
if
ic
an
t
1
.8
-f
o
ld
in
cr
e
as
e
d
ri
sk
o
f
ca
n
ce
r
W
o
lf
f
(2
0
1
0
)
U
SA
R
e
tr
o
sp
e
ct
iv
e
B
la
d
d
e
r
T
is
su
e
P
yr
o
se
q
u
e
n
ci
n
g
1
1
3
/6
3
C
as
e
s
sh
o
w
e
d
a
d
e
cr
e
as
e
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
co
m
p
ar
e
d
w
it
h
co
n
tr
o
ls
Y
e
g
n
as
u
b
ra
m
an
ia
n
(2
0
0
8
)
U
SA
R
e
tr
o
sp
e
ct
iv
e
P
ro
st
at
e
T
is
su
e
C
O
M
P
A
R
E
7
6
/2
4
C
as
e
s
sh
o
w
e
d
a
d
e
cr
e
as
e
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
co
m
p
ar
e
d
w
it
h
co
n
tr
o
ls
Z
h
u
(2
0
1
1
)
U
SA
R
e
tr
o
sp
e
ct
iv
e
V
ar
io
u
s
B
lo
o
d
P
yr
o
se
q
u
e
n
ci
n
g
2
0
5
/4
8
7
In
d
iv
id
u
al
s
w
it
h
lo
w
e
st
LI
N
E-
1
m
e
th
yl
at
io
n
le
ve
ls
h
ad
a
si
g
n
if
ic
an
t
4
.4
-f
o
ld
in
cr
e
as
e
d
in
ci
d
e
n
ce
o
f
lu
n
g
ca
n
ce
r.
N
o
si
g
n
if
ic
an
t
as
so
ci
at
io
n
s
w
e
re
o
b
se
rv
e
d
fo
r
o
th
e
r
tu
m
o
rs
(*
)
St
u
d
ie
s
in
cl
u
d
e
d
in
th
e
m
e
ta
-a
n
al
ys
is
(N
=
1
9
).
A
Q
A
M
A
-P
C
R
:
A
b
so
lu
te
Q
u
an
ti
ta
ti
ve
A
ss
e
ss
m
e
n
t
O
f
M
e
th
yl
at
e
d
A
lle
le
s
P
C
R
,
C
O
B
R
A
LI
N
E-
1
:
C
o
m
b
in
e
d
B
is
u
lf
it
e
R
e
st
ri
ct
io
n
A
n
al
ys
is
LI
N
E-
1
,
C
O
M
P
A
R
E:
C
o
m
b
in
at
io
n
O
f
M
e
th
yl
at
e
d
D
N
A
P
re
ci
p
it
at
io
n
A
n
d
R
e
st
ri
ct
io
n
En
zy
m
e
d
ig
e
st
io
n
,
C
R
C
:
C
o
lo
re
ct
al
C
an
ce
r,
FC
C
X
:
Fa
m
ili
al
C
o
lo
re
ct
al
C
an
ce
r
ty
p
e
X
,
FL
C
:
Fi
b
ro
la
m
e
lla
r
C
ar
ci
n
o
m
a,
G
IS
T
:
G
as
tr
o
in
te
st
in
al
St
ro
m
al
T
u
m
o
rs
,
LI
N
E-
1
:
Lo
n
g
In
te
rs
p
e
rs
e
d
N
u
cl
e
o
ti
d
e
El
e
m
e
n
t
1
,
M
SI
:
M
ic
ro
Sa
te
lli
te
In
st
ab
le
,
M
S-
M
LP
A
:
M
e
th
yl
at
io
n
-S
p
e
ci
fi
c
M
u
lt
ip
le
x
Li
g
at
io
n
-d
e
p
e
n
d
e
n
t
P
ro
b
e
A
m
p
lif
ic
at
io
n
,
M
SS
:
M
ic
ro
Sa
te
lli
te
St
ab
le
,
Q
U
B
R
A
:
Q
u
an
ti
ta
ti
ve
B
is
u
lf
it
e
R
e
st
ri
ct
io
n
A
n
al
ys
is
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
9
4
7
8
.t
0
0
1
Hypomethylation and Cancer: A Meta-Analysis
PLOS ONE | www.plosone.org 8 October 2014 | Volume 9 | Issue 10 | e109478
Statistical Analysis
All data were analyzed using the REVIEW MANAGER 5.2
software provided by the Cochrane Collaboration (http://ims.
cochrane.org/revman).
The random-effects model was used to estimate weighted mean
differences (MDs) with 95% CI [18] and thus, no adjustment for
environmental effects was taken into account. Furthermore,
subgroup analyses were conducted by sample type (tissue or blood
samples), by sample source (fresh tissue or formalin-fixed, paraffin-
embedded, FFPE tissue), by cancer types (colorectal, stomach,
hepatocellular), and by assays used to measure global DNA
methylation levels. Forest plots were generated to illustrate the
study-specific effect sizes along with a 95% CI. Heterogeneity
across studies, was measured using the Q-test based on the x2
statistic, considering significant statistical heterogeneity as p,0.1.
As Cochran’s test only indicates the presence of heterogeneity
and not its magnitude, we also reported the I2 statistic, which
estimates the percentage of outcome variability that can be
attributed to heterogeneity across studies. An I2 value of 0%
denotes no observed heterogeneity, whereas, 25% is ‘‘low’’, 50%
is ‘‘moderate’’ and 75% is ‘‘high’’ heterogeneity [19]. We also
estimated the between-study variance using tau-squared (t2)
statistic [20].
To determine the presence of publication bias, the symmetry of
the funnel plots in which mean differences were plotted against
their corresponding standard errors were assessed.
Figure 2. Forest plot of the mean difference of LINE-1 methylation levels between cancer and control groups in tissue and blood
samples. Subgroup analysis based on sample type.
doi:10.1371/journal.pone.0109478.g002
Hypomethylation and Cancer: A Meta-Analysis
PLOS ONE | www.plosone.org 9 October 2014 | Volume 9 | Issue 10 | e109478
Results
Data extraction
The detailed steps of the systematic review and meta-analysis
process are given as a PRISMA flow chart in Figure 1. A total of
324 articles were retrieved from the database, one article was
added through manual searching with reference list and thus 46
papers, published between 2004 and 2014, were included in the
systematic review and summarized in Table 1 by cancer site or
type.
Data characteristics and quality assessment
A total of 18 studies were from Asian countries (40%), 13 from
European countries (28%), 13 from USA (28%) and 1 from
Argentina and from Egypt (2%, each).
Thirty-eight retrospective longitudinal studies compared LINE-
1 methylation levels between cancer patients and healthy subjects
or normal adjacent tissues in cancer patients. Eight prospective
longitudinal studies analysed LINE-1 methylation levels in cohorts
of cancer patients, in relation to the life expectancy, the outcome
of the disease or the malignancy of the tumor, identifying the role
of LINE-1 hypomethylation as a biomarker of poor prognosis in
cancer patients [15,21–27].
In 41 studies LINE-1 methylation levels were evaluated both in
tumor and in healthy controls tissues, and in the remaining 5
studies only in cancer patients.
Overall, the studies detected LINE-1 methylation levels in
15332 samples: 8103 from cancer patients (4679 tissue samples,
3276 blood samples ,72 oral rinses and 76 bone marrow plasma
cells) and 7136 control samples (6277 from healthy subjects and
859 from normal adjacent tissues in cancer patients).
Regarding the experimental methods to measure LINE-1
methylation levels, the ‘‘gold standard’’ method, used in 63% of
studies, was the pyrosequencing of bisulphite converted DNA.
Furthermore, 9 studies used combined bisulphite restriction
analysis of LINE-1 (COBRA LINE-1) and 8 studies used other
methods, i.e. sequencing, real-time PCR, AQAMA PCR, COM-
PARE methylation assay, MulticolorMethyLight Assay and MS-
MLPA.
Figure 3. Forest plot of the mean difference of LINE-1 methylation levels between cancer and control groups in tissue samples.
Subgroups analysis based on sample source.
doi:10.1371/journal.pone.0109478.g003
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The most frequent tumor type in study was colorectal cancer
analyzed in eight studies [15,21,28–33], followed by seven studies
that evaluated methylation level in gastric cancer [23,27,32,34–
37], five in hepatocellular carcinoma [25,38–41], four in bladder
cancer [1,14,42,43] and head and neck carcinoma [10,44–46],
two in lung cancer [47,48] and breast cancer [24,49], and single
studies assessed methylation levels in renal cell cancer [50],
prostate cancer [51], neuroendocrine tumor [52], ovarian cancer
[53], thyroid cancer [54], esophageal cancer [26], cervix cancer
[55], endometrial cancer [32], skin melanoma [22], testicular
cancer [56], leukemia [57], multiple myeloma [58], paragangli-
oma [59], fibrolamellar carcinoma [60] and gastrointestinal [61].
Four studies evaluated methylation level in several cancer sites
[13,28,29,32]. With regard to the assay method, pyrosequencing
was used in 29 studies, followed by COBRA in 9 studies, Real-
Time PCR and AQAMA-PCR in 2 studies. MulticolorMethy-
Light Assay, MS-MLP, COMPARE and QUBRA were adopted
in single study each.
Meta-analysis
Of the 46 selected papers, 14 reported means and SD of DNA
methylation levels. In addition, means and SDs were indepen-
dently calculated using data from 2 articles and, among Authors
contacted for missing data, 3 responded to the email requests and
data were added in the analysis [30,50,56]. Thus, 19 unique
articles were included in the quantitative analysis. Furthermore,
two papers by Antelo et al. [28] and by Pavicic et al. [32], reported
data from different cancer types and thus, they were separated in 4
and 8 sub-studies, respectively (Table 1).
A total of 6107 samples were included in the analysis: 2554 from
cancer patients (1127 tissue samples and 1427 blood samples) and
3553 control samples (2811 from healthy subjects and 742 from
normal adjacent tissues in cancer patients).
LINE-1 methylation levels were significantly lower in cancer
patients than in control samples (MD: 26.40, 95% CI: 27.71, 2
5.09; p,0.001). However, heterogeneity between studies was
significantly high (I2 = 99%) (Figure 2), thus, subgroup analysis
based on sample type (tissue or blood samples) was performed.
Figure 4. Forest plot of the mean difference of LINE-1 methylation levels between cancer and control groups. Subgroups analysis
based on cancer type.
doi:10.1371/journal.pone.0109478.g004
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The significant difference in methylation levels was confirmed in
tissue samples (MD 27.55; 95% CI: 29.14, 265.95; p,0.001),
but not in blood samples (MD: 20.26, 95% CI: 20.69, 0.17;
p = 0.23).
A subgroup analysis by sample source was conducted. LINE-1
methylation levels were significantly lower in cancer patients than
in control samples in fresh and/or frozen tissue (MD 28.19; 95%
CI: 210.54, 25.84; p,0.001) and in FFPE tissue (MD: 26.96;
95% CI:29.73, 24.20; p,0.001). Heterogeneity between studies,
in the two subgroups was significantly high (I2 = 98% and 96%
respectively) (Figure 3).
Furthermore, a subgroup analysis by specific cancer types, for
colorectal, hepatocellular and gastric cancer, was conducted.
LINE-1 methylation levels were significantly lower in colorectal
and gastric cancer patients than in control samples (MD: 28.33;
95% CI: 210.56, 26.10; p,0.001 and MD: 25.75; 95% CI: 2
7.75, 23.74; p,0.001). No difference of LINE-1 methylation
levels in blood leukocytes was observed for hepatocellular cancer
(MD: 25.76; 95% CI: 212.03, +0.51; p = 0.23). Heterogeneity
between studies, in colorectal and hepatocellular subgroups was
significantly high (I2 = 96%), and moderately high in the gastric
subgroups (I2 = 66%) (Figure 4).
A subgroup analysis by assays used to measure the methylation
levels, and particularly, between the two commonly used
techniques, pyrosequencing and COBRA LINE-1, was performed.
The MDs for pyrosequencing and COBRA LINE-1 subgroups
were -7.33 (95% CI: 29.06, 25.59; p,0.001) and 25.75 (95%
CI: 27.13, 24.37; p = 0.03), respectively. Heterogeneity between
studies and in the pyrosequencing subgroup was significantly high
(I2 = 100%), and moderately high in the COBRA subgroup
(I2 = 63%) (Figure 5).
A subgroup analysis by sample type, particularly tissue samples,
and assay method was conducted. The MDs in the subgroups of
studies which detected LINE-1 methylation levels in tissue samples
through pyrosequencing and COBRA LINE-1, were 210.42
(95% CI: 212.93, 27.91; p,0.001) and 25.12 (95% CI: 26.33,
23.91; p = 0.10), respectively. Heterogeneity between studies and
in the pyrosequencing subgroup was significantly high (I2 = 97%),
moderately high in COBRA LINE-1 subgroup (I2 = 56%)
(Figure 6). Stratification among studies which detected LINE-1
methylation in blood samples was not performed due to the
paucity of studies.
The funnel plots indicate small to moderate asymmetry,
suggesting that publication bias cannot be completely excluded
as a factor of influence on the present meta-analysis (Figures 7–
12).
Figure 5. Forest plot of the mean difference of LINE-1 methylation levels between cancer and control groups. Subgroups analysis
based on method.
doi:10.1371/journal.pone.0109478.g005
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Figure 6. Forest plot of the mean difference of LINE-1 methylation levels between cancer and control groups in tissue samples.
Subgroups analysis based on method.
doi:10.1371/journal.pone.0109478.g006
Figure 7. Funnel plot. Subgroup analysis based on sample type.
doi:10.1371/journal.pone.0109478.g007
Hypomethylation and Cancer: A Meta-Analysis
PLOS ONE | www.plosone.org 13 October 2014 | Volume 9 | Issue 10 | e109478
Figure 8. Funnel plot. Subgroup analysis based on tissue specimen types. SE, standard error, MD, mean difference.
doi:10.1371/journal.pone.0109478.g008
Figure 9. Funnel plot. Subgroup analysis based on cancer type in blood samples.
doi:10.1371/journal.pone.0109478.g009
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Figure 10. Funnel plot. Subgroup analysis based on cancer type in tissue samples.
doi:10.1371/journal.pone.0109478.g010
Figure 11. Funnel plot. Subgroup analysis based on detection method in blood samples.
doi:10.1371/journal.pone.0109478.g011
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Discussion
The low level of DNA methylation in tumors compared with
DNA methylation level in their normal-tissue counterparts was
one of the first epigenetic alterations to be found in human cancer
[62]. The loss of methylation is mainly due to hypomethylation of
repetitive DNA sequences and LINE-1 elements are typically
heavily methylated in normal tissues, while LINE-1 hypomethyla-
tion has been reported in cancer tissues. Furthermore, Liao et al.
[50] reported that LINE-1 methylation levels, measured in
leukocyte DNA, were significantly higher in renal cancer patients
than in healthy subjects.
Two recent meta-analyses were conducted in order to estimate
overall cancer risk according to global DNA hypomethylation in
blood leukocytes. The meta-analysis by Woo and Kim [11] reports
that global DNA hypomethylation of blood leukocytes was
associated with increased cancer risk, although the association
varied by the experimental methods used (% 5- methylcytosine
method, LINE-1 with pyrosequencing and methyl acceptance
assay), the region of DNA targeted and the cancer type. An
updated meta-analysis performed by Brennan and Flanagan [16]
indicates a significant inverse association between genomic 5-
methylcytosine levels and cancer risk (OR =3.65; 1.20–6.09), but
no overall risk association for studies using surrogates for genomic
methylation, including methylation at the LINE-1 repetitive
element (OR =1.24; 0.76–1.72). Notably, the previous two
meta-analyses included studies reporting association analysis
between blood methylation levels and cancer risk but did not
evaluate studies reporting differences in mean methylation levels in
blood and in other tissues. The present meta-analysis of recent
reports was conducted including studies reporting methylation
levels in blood and in other tissues. This meta-analysis concerned
19 unique articles, but since two articles comprised more than one
study conducted on different patient populations, altogether there
were 29 non-unique studies included. On a total of 2554 samples
from cancer patients and 3553 control samples, this meta-analysis
reports that mean methylation levels in cancer patients were
significantly 6.4% lower than in control samples.
The association between cancer risk and global DNA methyl-
ation has been mostly investigated in blood samples, because
harvesting tumor tissue is invasive and cannot be routinely
performed. However, several studies have reported that methyl-
ation of repetitive elements is tissue specific, most variable in
tumor tissue, and is not correlated between tumor and blood [63–
65]. Consistently, evidence reveals that genomic hypomethylation
in tumor and normal adjacent tissue of bladder and colon cancer
was not detectable in blood [43,66], suggesting that hypomethyla-
tion is restricted to the disease affected tissue. Interestingly, in the
present meta-analysis the significant difference in mean methyl-
ation levels was confirmed only in tissue samples, both fresh/
frozen or FFPE specimens, but not in blood samples. Furthermore,
the meta-analysis provided sufficient evidence that LINE-1
hypomethylation, significantly increases in colorectal and gastric
cancer. On the contrary, no overall association was found for
hepatocellular carcinoma. Notably, all studies focusing on
colorectal and gastric tumors evaluated LINE-1 methylation in
tissue samples, while all the included studies on hepatocellular
carcinoma investigated the association only in blood leukocyte
samples. Global DNA methylation can be measured by direct and
indirect quantification assays. Although the measurement of
percentages of 5- methylcytosine to estimate global DNA
methylation contents are highly quantitative and reproducible,
they require high amount of DNA and are not suitable for large
epidemiological studies. Pyrosequencing with bisulfite-treated
DNA, the "gold standard" for DNA methylation analysis
[67,68], is a high-throughput and accurate method currently
available to measure LINE-1 methylation as surrogate marker for
global DNA hypomethylation. However, LINE-1 methylation
Figure 12. Funnel plot. Subgroup analysis based on detection method in tissue samples.
doi:10.1371/journal.pone.0109478.g012
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levels can vary depending on the target CpG sequence detected
[69], representing an important factor in the association study with
cancer risk. In the present meta-analysis, considering the two most
frequently used detection methods (pyrosequencing and COBRA
LINE-1) both subgroups report significantly lower LINE-1
methylation levels in cancer patients than in control samples,
although heterogeneity between studies was significantly high in
the pyrosequencing subgroup and moderately high in the COBRA
subgroup.
The main limitations of this meta-analysis are the small number
of studies included (n= 19) and the high heterogeneity across
studies. Although a random effects model was performed, in order
to take into account the high heterogeneity, the pooled estimates
should be interpreted with caution. To overcome this issue, pooled
estimates were calculated in more homogeneous subsets of studies
(subgroups analysis). In addition, the possible existence of a
publication bias was considered. Examination of funnel plots
showed small to moderate asymmetry, suggesting that publication
bias cannot be completely excluded and may have had at least a
moderate impact on the true effect size estimates. In fact, some
data, such as conference abstracts, non-English literature, unpub-
lished data and other inconsistent reports according to our
selection criteria were excluded. Furthermore, methylation-risk
association tend only to be reported if it reveals statistically
significant results, and if the authors deem analysis appropriate
[16].
Moreover, since most studies (83%) had a case-control design
large cohort studies are needed in order to clarify if global
hypomethylation is an early cancer-causing aberration or an effect
of carcinogenesis [11].
In conclusion, the present meta-analysis adds new evidence to
the growing literature on the role of LINE-1 hypomethylation in
human cancer and shows that LINE-1 methylation levels were
significantly lower in cancer patients than in controls, especially for
certain cancer types. This result was confirmed in tissue samples
but not in blood. Further studies are needed to better clarify the
role of LINE-1 methylation in specific subgroups, considering both
the cancer and sample type, and the methods of measurement.
Supporting Information
Checklist S1 PRISMA Checklist.
(DOC)
Checklist S2 Meta-analysis on Genetic Association
Studies Checklist.
(DOC)
Acknowledgments
The Authors would like to thank the Authors A. Goel and K. Hur and
colleagues, L.M. Liao and L. E. Moore and colleagues and M.H. Greene
and L. Mirabello and colleagues for supporting more data not reported in
their articles.
Author Contributions
Conceived and designed the experiments: MV AA. Performed the
experiments: MB AQ AM. Analyzed the data: MB AA. Contributed
reagents/materials/analysis tools: MB AQ AM. Wrote the paper: MB MV
AA.
References
1. Cash H, Tao L, Yuan JM, Marsit C, Houseman E, et al. (2012) LINE-1
hypomethylation is associated with bladder cancer risk among non-smoking
Chinese. Int J Cancer 130: 1151–1159.
2. Laird PW, Jaenisch R (1994) DNA methylation and cancer. Hum Mol Genet 3:
1487–1496.
3. Jones PA (1996) DNA methylation errors and cancer. Cancer Res 56: 2463–
2467.
4. Liu L, Wylie RC, Andrews LG, Tollefsbol TO (2003) Aging, cancer and
nutrition: the DNA methylation connection. Mech Ageing Dev 124: 989–998.
5. Davis CD, Uthus EO (2004) DNA methylation, cancer susceptibility, and
nutrient interactions. Exp Biol Med 229: 988–995.
6. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R (1998) DNA
hypomethylation leads to elevated mutation rates. Nature 395: 89–93.
7. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial
sequencing and analysis of the human genome. Nature 409: 860–921.
8. Rodriguez J, Frigola J, Vendrell E, Risques RA, Fraga MF, et al. (2006)
Chromosomal instability correlates with genomewide DNA demethylation in
human primary colorectal cancers. Cancer Res 66: 8462–9468.
9. Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, et al. (2005) Molecular
classification of multiple myeloma: a distinct transcriptional profile characterizes
patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol
23: 7296–7306.
10. Fabris S, Ronchetti D, Agnelli L, Baldini L, Morabito F, et al. (2007)
Transcriptional features of multiple myeloma patients with chromosome 1q
gain. Leukemia, 21: 1113–1116.
11. Woo HD, Kim J (2012) Global DNA Hypomethylation in Peripheral Blood
Leukocytes as a Biomarker for Cancer Risk: A Meta-Analysis. PLoS ONE
7:e34615.
12. Hsiung D, Marsit C, Houseman E, Eddy K, Furniss C, et al. (2007) Global DNA
Methylation Level in Whole Blood as a Biomarker in Head and Neck Squamous
Cell Carcinoma. Cancer Epidemiol Biomarkers Prev 16: 108–114.
13. Zhu ZZ, Sparrow D, Hou L, Tarantini L, Bollati V, et al. (2011) Repetitive
element hypomethylation in blood leukocyte DNA and cancer incidence,
prevalence and mortality in elderly individuals: the Normative Aging Study.
Cancer Causes Control 22: 437–447.
14. Wilhelm C, Kelsey K, Butler R, Plaza S, Gagne L, et al. (2010) Implications of
LINE1 Methylation for Bladder Cancer Risk in Women. Clin Cancer Res 16:
1682–1689.
15. Baba Y, Huttenhower C, Nosho K, Tanaka N, Shina K, et al. (2010)
Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a
database of 869 tumors. Molecular Cancer 9: 125.
16. Brennan K, Flanagan JM (2012) Is there a link between genome-wide
hypomethylation in blood and cancer risk? Cancer Prev Res (Phila) 5: 1345–
1357.
17. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2010) Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. Int J Surg 8: 336–341.
18. Higgins J, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency
in meta-analyses. BMJ 327: 557–560.
19. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis.
Stat Med 21: 1539–1558.
20. Higgins JPT, Green S (2008) Cochrane handbook for systematic reviews of
interventions Version 5.0.0 updated February 2008. The Cochrane Collabora-
tion.
21. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, et al. (2012) A cohort
study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl
Cancer Inst 100: 1734–1738.
22. Sigalotti L, Fratta E, Bidoli E, Covre A, Parisi G, et al. (2011) Methylation levels
of the ‘‘long interspersed nucleotide element-1’’ repetitive sequences predict
survival of melanoma patients. J Transl Med 9: 78.
23. Bae JM, Shin SH, Kwon HJ, Park SY, Kook M, et al. (2012) ALU and LINE-1
hypomethylations in multistep gastric carcinogenesis and their prognostic
implications. Int J Cancer 131: 1323–1331.
24. Van Hoesel A, van de Velde C, Kuppen P, Liefers G, Putter H, et al. (2012)
Hypomethylation of LINE-1 in primary tumor has poor prognosis in young
breast cancer patients: a retrospective cohort study. Breast Cancer Res Treat
134: 1103–1114.
25. Gao XD, Qu JH, Chang XJ, Lu YY, Bai WL, et al. (2013) Hypomethylation of
long interspersed nuclear element-1 promoter is associated with poor outcomes
for curative resected hepatocellular carcinoma. Liver Int 34: 136–146.
26. Iwagami S, Baba Y, Watanabe M, Shigaki H, Miyake K, et al. (2013) LINE-1
Hypomethylation Is Associated With a Poor Prognosis Among Patients With
Curatively Resected Esophageal Squamous Cell Carcinoma. Ann Surg 257(3):
449–55.
27. Shigaki H, Baba Y, Watanabe M, Murata A, Iwagami S, et al. (2013) LINE-1
hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is
associated with poor prognosis. Gastric Cancer 16: 480–487.
28. Antelo M, Balaguer F, Shia J, Shen Y, Hur K, et al. (2012) A High Degree of
LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal
Cancer. PLoS ONE 7: e45357.
Hypomethylation and Cancer: A Meta-Analysis
PLOS ONE | www.plosone.org 17 October 2014 | Volume 9 | Issue 10 | e109478
29. Estecio MRH, Gharibyan V, Shen L, Ibrahim AEK, Doshi K, et al. (2007)
LINE-1 Hypomethylation in Cancer Is Highly Variable and Inversely
Correlated with Microsatellite Instability. PLoS ONE 2:e399.
30. Hur K, Cejas P, Feliu J, Moreno-Rubio J, Burgos E, et al. (2014)
Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to
activation of protooncogenes in human colorectal cancer metastasis. Gut 63:
635–646.
31. Matsunoki A, Kawakami K, Kotake M, Kaneko M, Kitamura H, et al. (2012)
LINE-1 methylation shows little intra-patient heterogeneity in primary and
synchronous metastatic colorectal cancer. BMC Cancer 12: 574.
32. Pavicic W, Joensuu E, Nieminen T, Peltoma¨ki P (2012) LINE-1 hypomethyla-
tion in familial and sporadic cancer. J Mol Med 90: 827–835.
33. Sunami E, de Maat M, Vu A, Turner RR, Hoon DSB (2011) LINE-1
Hypomethylation During Primary Colon Cancer Progression. PLoS ONE 6(4):
e18884.
34. Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijva-
nich P, et al. (2004) Distinctive pattern of LINE-1 methylation level in normal
tissues and the association with carcinogenesis. Oncogene 23: 8841–8846.
35. Hou L, Wang H, Sartori S, Gawron A, Lissowska J, et al. (2010) Blood leukocyte
DNA hypomethylation and gastric cancer risk in a high-risk Polish population.
Int J Cancer 127: 1866–1874.
36. Gao Y, Baccarelli A, Shu XO, Ji BT, Yu K, et al. (2012) Blood leukocyte Alu
and LINE-1 methylation and gastric cancer risk in the Shanghai Women’s
Health Study. Br J Cancer 106: 585–391.
37. Lee JR, Chung WC, Kim JD, Lee KM, Paik CN, et al. (2011) Differential LINE-
1 Hypomethylation of Gastric Low-Grade Dysplasia from High Grade Dysplasia
and Intramucosal Cancer. Gut Liver 5: 149–153.
38. Ramzy I, Omran D, Hamad O, Shaker O, Abboud A (2011) Evaluation of
serum LINE-1 hypomethylation as a prognostic marker for hepatocellular
carcinoma. Arab J Gastroenterol 12: 139–142.
39. Wu HC, Wang Q, Yang HI, Tsai WY, Chen CJ, et al. (2012) Global DNA
methylation levels in white blood cells as a biomarker for hepatocellular
carcinoma risk: a nested case–control study. Carcinogenesis 33: 1340–1345.
40. Tangkijvanich P, Hourpai N, Rattanatanyong P, Wisedopas N, Mahachai V,
et al. (2007) Serum LINE-1 hypomethylation as a potential prognostic marker
for hepatocellular carcinoma. Clin Chim Acta 379: 127–133.
41. Di JZ, Han XD, Gu WY, Wang Y, Zheng Q, et al. (2011) Association of
hypomethylation of LINE-1 repetitive element in blood leukocyte DNA with an
increased risk of hepatocellular carcinoma. J Zhejiang Univ-Sci B 12: 805–811.
42. Kreimer U, Schulz WA, Koch A, Niegisch G, Goering W (2013) HERV-K and
LINE-1 DNA methylation and reexpression in urothelial carcinoma. Frontiers in
Oncology 3: 255.
43. Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, et al. (2010)
Hypomethylation of a LINE-1 Promoter Activates an Alternate Transcript of
the MET Oncogene in Bladders with Cancer. PLoS Genet 6:e1000917.
44. Subbalekha K, Pimkhaokham A, Pavasant P, Chindavijak S, Phokaew C, et al.
(2009) Detection of LINE-1s hypomethylation in oral rinses of oral squamous
cell carcinoma patients. Oral Oncol 45: 184–191.
45. Phokaew C, Kowudtitham S, Subbalekha K, Shuangshoti S, Mutirangura A
(2008) LINE-1 methylation patterns of different loci in normal and cancerous
cells. Nucleic Acids Res 36: 5704–5712.
46. Pobsook T, Subbalekha K, Sannikorn P, Mutirangura A (2011) Improved
measurement of LINE-1 sequence methylation for cancer detection. Clin Chim
Acta 412; 314–321.
47. Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, et al. (2009)
Hypomethylation of retrotransposable elements correlates with genomic
instability in non-small cell lung cancer. Int J Cancer 124: 81–87.
48. Saito K, Kawakami K, Matsumoto I, Oda M, Watanabe G, et al. (2010) Long
Interspersed Nuclear Element 1 Hypomethylation Is a Marker of Poor Prognosis
in Stage IA Non–Small Cell Lung Cancer. Clin Cancer Res 16: 2418–2426.
49. Choi JY, James S, Link P, McCann S, Hong C, et al. (2009) Association between
global DNA hypomethylation in leukocytes and risk of breast Cancer.
Carcinogenesis 30: 1889–1897.
50. Liao LM, Brennan P, van Bemmel DM, Zaridze D, Matveev V, et al. (2011)
LINE-1 Methylation Levels in Leukocyte DNA and Risk of Renal Cell Cancer.
PLoS ONE 6:e27361.
51. Yegnasubramanian S, Haffner M, Zhang Y, Gurel B, Cornish TC, et al. (2008)
DNA Hypomethylation Arises Later in Prostate Cancer Progression than CpG
Island Hypermethylation and Contributes to Metastatic Tumor Heterogeneity.
Cancer Res 68: 8954–67.
52. Choi IS, Estecio M, Nagano Y, Kim DH, White J, et al. (2007) Hypomethyla-
tion of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic
endocrine tumors and carcinoid tumors). Modern Pathology 20: 802–810.
53. Dammann RH, Kirsch S, Schagdarsurengin U, Dansranjavin T, Gradhand E,
et al. (2010) Frequent aberrant methylation of the imprinted IGF2/H19locus
and LINE1 hypomethylation in ovarian carcinoma. Int J Oncol 36: 171–179.
54. Lee JJ, Geli J, Larsson C, Wallin G, Karimi M, et al. (2008) Gene-specific
promoter hypermethylation without global hypomethylation in follicular thyroid
cancer. Int J Oncol 33: 861–869.
55. Shuangshoti S, Hourpai N, Pumsuk U, Mutirangura A (2007) Line-1
Hypomethylation in Multistage Carcinogenesis of the Uterine Cervix. Asian
Pac J Cancer Prev 8: 307–309.
56. Mirabello L, Savage S, Korde L, Gadalla SM, Greene MH (2010) LINE-1
methylation is inherited in familial testicular cancer kindreds. BMC Med Genet
11: 77.
57. Fabris S, Bollati V, Agnelli L, Morabito F, Motta V, et al. (2011) Biological and
clinical relevance of quantitative global methylation of repetitive DNA sequences
in chronic lymphocytic leukemia. Epigenetics 6: 188–194.
58. Bollati V, Fabris S, Pegoraro V, Ronchetti D, Mosca L, et al. (2009) Differential
repetitive DNA methylation in multiple myeloma molecular subgroups.
Carcinogenesis 30: 1330–1335.
59. Geli J, Kiss N, Karimi M, Lee JJ, Backdahl M, et al. (2008) Global and Regional
CpG Methylation in Pheochromocytomas and Abdominal Paragangliomas:
Association to Malignant Behavior. Clin Cancer Res 14: 2551–2559.
60. Trankenschuh W, Puls F, Christgen M, Albat C, Heim A, et al. (2010) Frequent
and Distinct Aberrations of DNA Methylation Patterns in Fibrolamellar
Carcinoma of the Liver. PLoS ONE 5:e13688.
61. Igarashi S, Suzuki H, Niinuma T, Shimizu H, Nojima M, et al. (2010) Novel
Correlation between LINE-1 Hypomethylation and the Malignancy of
Gastrointestinal Stromal Tumors. Clin Cancer Res 16: 5114–5123.
62. Feinberg AP, Vogelstein B (1983) Hypomethylation distinguishes genes of some
human cancers from their normal counterparts. Nature 301: 89–92.
63. Zhu ZZ, Hou L, Bollati V, Tarantini L, Marinelli B, et al. (2010) Predictors of
global methylation levels in blood DNA of healthy subjects: a combined analysis.
Int J Epidemiol 41: 126–139.
64. Piyathilake CJ, Macaluso M, Alvarez RD, Chen M, Badiga S, et al. (2011) A
higher degree of LINE-1 methylation in peripheral blood mononuclear cells, a
one-carbon nutrient related epigenetic alteration, is associated with a lower risk
of developing cervical intraepithelial neoplasia. Nutrition 27: 513–59.
65. van Bemmel D, Lenz P, Liao LM, Baris D, Sternberg LR, et al. (2012)
Correlation of LINE-1 methylation levels in patient matched buffy coat, serum,
buccal cell and bladder tumor tissue DNA samples. Cancer Epidemiol
Biomarkers Prev 21: 1143–1148.
66. Suter CM, Martin DI, Ward RL (2004) Hypomethylation of L1 retro-
transposons in colorectal cancer and adjacent normal tissue. Int J Colorectal
Dis 19: 95–101.
67. Rakyan VK, Down TA, Balding DJ, Beck S (2011) Epigenome-wide association
studies for common human diseases. Nat Rev Genet 12: 529–541.
68. Beck S, Rakyan VK (2008) The methylome: approaches for global DNA
methylation profiling. Trends Genet 24: 231–237.
69. Nelson H, Marsit C, Kelsey K (2011) Global Methylation in Exposure Biology
and Translational Medical Science. Environ Health Perspect 119: 1528–1533.
Hypomethylation and Cancer: A Meta-Analysis
PLOS ONE | www.plosone.org 18 October 2014 | Volume 9 | Issue 10 | e109478
